文献速递糖尿病

低剂量恩格列净辅助混合闭环胰岛素治疗控制不佳成人1型糖尿病:随机交叉对照试验

Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial.
PubMed 文献 · Diabetes Care · 2023-01-01

这项双盲随机交叉对照试验纳入24例血糖控制不佳的1型糖尿病成人(HbA1c 8.1±0.5%),比较安慰剂、2.5 mg和5 mg恩格列净辅助混合闭环治疗的14天效果;两种剂量恩格列净均使目标范围内时间(3.9-10.0 mmol/L)较安慰剂提高11-13个百分点,无严重不良事件或糖尿病酮症酸中毒、严重低血糖发生;作者指出需未来研究评估长期疗效和安全性。

要点

  • 2.5 mg和5 mg恩格列净辅助混合闭环治疗均较安慰剂提高目标范围内时间约11-13个百分点。
  • 两种剂量恩格列净与安慰剂组间日均毛细血管酮体水平无差异。
  • 各干预组均无严重不良事件、糖尿病酮症酸中毒或严重低血糖病例。

核心结论

  • 在混合闭环治疗下,2.5 mg和5 mg恩格列净较安慰剂使目标范围内时间提高11-13个百分点,适用于单用该系统无法达标者。
  • 作者指出需未来研究评估长期疗效和安全性。

研究设计与样本

  • 双盲交叉随机对照试验,纳入HbA1c 7.0-10.5%且经14天混合闭环治疗未能达到目标范围内时间(3.9-10.0 mmol/L)≥70%的控制不佳1型糖尿病成人。
  • 共24例完成研究(50%男性;年龄33±14岁;HbA1c 8.1±0.5%)。
  • 进行三个14天干预:安慰剂、2.5 mg恩格列净或5 mg恩格列净辅助McGill人工胰腺。
  • 参与者按1:1:1:1:1:1比例分组,采用区组随机化。
  • 主要结局为目标范围内时间(3.9-10.0 mmol/L),按意向性分析,P值<0.05视为显著。

主要发现

  • 目标范围内时间:安慰剂组59.0±9.0%,2.5 mg恩格列净组71.6±9.7%,5 mg恩格列净组70.2±8.0%。
  • 2.5 mg恩格列净与安慰剂之间、5 mg恩格列净与安慰剂之间P值均<0.0001。
  • 日均毛细血管酮体水平在各组间无差异。
  • 各干预组均无严重不良事件、糖尿病酮症酸中毒或严重低血糖病例。

关键数值与推荐

  • 主要结局目标范围内时间(3.9-10.0 mmol/L):安慰剂组59.0±9.0%,2.5 mg恩格列净组71.6±9.7%,5 mg恩格列净组70.2±8.0%。
  • 2.5 mg恩格列净与安慰剂比较P<0.0001,5 mg恩格列净与安慰剂比较P<0.0001。
  • 日均毛细血管酮体水平在各组间无差异。
  • 各干预组均无严重不良事件、糖尿病酮症酸中毒或严重低血糖病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需未来研究评估长期疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether low doses of empagliflozin as adjunct to hybrid closed-loop therapy improve glycemia compared with placebo in adults with type 1 diabetes (T1D) who are not able to achieve targets with the system alone. RESEARCH DESIGN AND METHODS: A double-blind crossover randomized controlled trial was performed in adults with suboptimally controlled T1D (HbA1c 7.0-10.5%) who were not able to achieve a target time in range (3.9-10.0 mmol/L) ≥70% after 14 days of hybrid closed-loop therapy. Three 14-day interventions were performed with placebo, 2.5 mg empagliflozin, or 5 mg empagliflozin as adjunct to the McGill artificial pancreas. Participants were assigned at a 1:1:1:1:1:1 ratio with blocked randomization. The primary outcome was time in range (3.9-10.0 mmol/L). Analysis was by intention to treat, and a P value <0.05 was regarded as significant. RESULTS: A total of 24 participants completed the study (50% male; age 33 ± 14 years; HbA1c 8.1 ± 0.5%). The time in range was 59.0 ± 9.0% for placebo, 71.6 ± 9.7% for 2.5 mg empagliflozin, and 70.2 ± 8.0% for 5 mg empagliflozin (P < 0.0001 between 2.5 mg empagliflozin and placebo and between 5 mg empagliflozin and placebo). Mean daily capillary ketone levels were not different between arms. There were no serious adverse events or cases of diabetic ketoacidosis or severe hypoglycemia in any intervention. CONCLUSIONS: Empagliflozin at 2.5 and 5 mg increased time in range during hybrid closed-loop therapy by 11-13 percentage points compared with placebo in those who otherwise were unable to attain glycemic targets. Future studies are required to assess long-term efficacy and safety.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Pasqua MR, Jafar A, Kobayati A, et al. Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial. Diabetes Care. 2023. PMID: 36331522. doi:10.2337/dc22-0490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。